Catalan Pharmaceutical Group Plans Major Production and Research Hub in Switzerland
A new international pharmaceutical investment is planned for western Switzerland, where Barcelona-based STE Pharmaceuticals intends to establish a manufacturing and research center in Couvet, a village in the canton of Neuchâtel. The proposed development could strengthen the region’s position as an emerging pharmaceutical production location while bringing additional skilled employment opportunities to an area traditionally associated with watchmaking.
The company is planning a development covering approximately 15,000 square meters, combining pharmaceutical manufacturing facilities with a research and development department. Construction and conversion work are expected to be completed by 2032, according to information released on November 2, 2026.
The project involves transforming a former pharmaceutical manufacturing facility previously operated by Analytecon. A building permit application has been submitted, although the development remains subject to the necessary planning and authorization procedures.
For Neuchâtel, the proposed investment represents another opportunity to attract international pharmaceutical businesses and diversify the local economy beyond its established industrial sectors.
A Barcelona-based group prepares its Swiss expansion
STE Pharmaceuticals is a Catalan pharmaceutical group headquartered in Barcelona, Spain. The company operates in more than 60 countries and specializes in products including nasal sprays, cough syrups and natural food supplements.
Its planned Swiss presence will operate through STE Swiss Pharma, a locally established entity created to manage the group’s expansion into Switzerland.
Stefano Ponta, director of STE Swiss Pharma, confirmed the development plans in comments to regional broadcaster RTN. He said the expanded site would incorporate modern technology and provide opportunities for qualified employment.
The company has not yet announced how many positions it expects to create. Ponta indicated that it remains too early to provide a reliable employment estimate while the project is still being developed.
Nevertheless, the inclusion of research and development alongside manufacturing suggests that the proposed facility is intended to have a broader role than simply producing pharmaceutical products for existing markets.
Establishing research capabilities in Switzerland would also give the group a presence in a country internationally recognized for pharmaceutical research, manufacturing expertise and life sciences development. Former pharmaceutical factory selected for redevelopment
Rather than establishing an entirely new industrial location, STE Pharmaceuticals intends to redevelop the former Analytecon pharmaceutical factory in Couvet.
The proposed transformation includes demolition work and the construction or redevelopment necessary to accommodate the planned 15,000-square-meter operation.
A building permit application has already been submitted to the relevant authorities. The public consultation period is scheduled to remain open until November 9, 2026.
This stage is important because the proposed development has not yet received final planning authorization. The consultation process gives the relevant authorities and interested parties an opportunity to examine the application before decisions are made.
The company’s target of completing the development by 2032 therefore remains a project objective rather than a confirmed opening date.
The reuse of an existing pharmaceutical location could provide a foundation for the investment, although the extent of demolition, construction and technical redevelopment will depend on the approved plans.
For Couvet, the project represents a potential continuation of industrial activity at a site with an existing pharmaceutical history.
Why Neuchâtel is attracting pharmaceutical companies
The proposed investment comes as Couvet develops a stronger concentration of pharmaceutical businesses.
Three other pharmaceutical companies already have operations in the village: WuXi AppTec through its WuXi STA subsidiary, Sintetica and GMT Fine Chemicals.
The arrival of STE Pharmaceuticals would add another international participant to this growing industrial environment.
The presence of several companies operating within the same sector can create opportunities for specialized employment, technical cooperation and the development of supporting services.
For pharmaceutical manufacturers, access to experienced employees, industrial infrastructure and an established business environment can be important considerations when selecting locations for production and research facilities.
The canton of Neuchâtel is also seeking to broaden its economic base. Although the region has a strong industrial identity, Val-de-Travers remains significantly associated with the watchmaking sector.
Matthieu Aubert, head of the cantonal employment service, welcomed the prospect of attracting another international company. He said investments of this kind could diversify the economic structure of Val-de-Travers and the wider canton.
He also highlighted the potential for Couvet to develop into a pharmaceutical cluster capable of attracting qualified workers.
Existing investment demonstrates Couvet’s manufacturing potential
STE Pharmaceuticals will not be entering an entirely new pharmaceutical environment.
One of the area’s most significant recent industrial developments has been the expansion of WuXi AppTec’s manufacturing activities.
In October 2026, the group announced the opening of a new spray-drying production facility at its Couvet site following an investment of approximately $100 million.
The facility is designed to support the production of pharmaceutical formulations using spray-drying technology, which can improve the solubility and absorption of certain medicines.
The investment was part of a wider strategy to strengthen the site’s role in the company’s European manufacturing network.
According to Greater Geneva Bern area, the new production line is expected to create approximately 15 additional jobs. The existing workforce at the site already exceeds 150 employees.
WuXi AppTec acquired the former Bristol Myers Squibb manufacturing facility in Couvet in 2021. That transaction established the location as an important part of the company’s European pharmaceutical operations.
The investment history provides useful context for the proposed STE Pharmaceuticals development: Couvet is already attracting capital for specialized pharmaceutical manufacturing rather than relying solely on future investment promises.
Research and development could broaden the region’s industrial base
One of the most important aspects of the STE Pharmaceuticals proposal is its intention to establish a dedicated research and development department.
Manufacturing operations can create industrial employment, but research facilities also require specialized scientific, technical and development expertise.
If completed as planned, the Couvet site could therefore contribute to a wider range of professional opportunities within the region.
The combination of production and research activities may also strengthen the area’s attractiveness to employees with pharmaceutical, chemical and technical qualifications.
However, the company has not yet disclosed its expected workforce size, research investment budget or the precise products that would be manufactured at the Swiss facility.
Those details will be important in assessing the project’s eventual economic contribution.
A 15,000-square-meter development is a substantial industrial undertaking, but its physical size alone cannot establish how many permanent jobs or how much additional economic activity it will generate.
The actual impact will depend on the facility’s final configuration, production capacity, recruitment plans and operational schedule.
A longer-term opportunity for Switzerland’s pharmaceutical industry
Switzerland has an established pharmaceutical sector, with internationally recognized companies and a network of specialized research, development and manufacturing organizations.
The planned Couvet investment adds another potential international connection to that industrial landscape.
For STE Pharmaceuticals, establishing a Swiss presence could provide access to the country’s pharmaceutical expertise and a location for expanding its production and research activities.
For Neuchâtel, the development offers an opportunity to attract additional investment into a region seeking greater economic diversification.
The immediate milestone is the completion of the planning authorization process, with public consultation scheduled to end on November 9.
Beyond that, the company faces the longer process of transforming the former factory into a modern manufacturing and research complex.
If the project proceeds according to its current timetable, Couvet could gain another significant pharmaceutical operation by 2032.
The investment’s eventual importance will be measured not simply by the size of the proposed buildings, but by the skilled employment, research capabilities and sustained industrial activity it brings to the region.
For now, STE Pharmaceuticals’ plans represent another indication that Couvet is becoming an increasingly important location in Switzerland’s developing pharmaceutical manufacturing landscape.
